Delivering on the Promise:
Checkpoint Blockade in Cancer Immunotherapy

Akintunde Bello_Circle.jpg

Presented by Akintunde Bello,
Executive Director, Bristol-Myers Squibb

Cancer immunotherapy is the identification of and therapeutic intervention in mechanisms by which cancer evades recognition and destruction by the immune system.                                                


In your own time, hear: 

  • An overview of the development of immune checkpoint inhibition as a therapeutic approach in the treatment of cancer
  • Discussion of the features and impact of checkpoint inhibitors on the treatment of various cancers with particular attention to the PD1 inhibitor nivolumab

Fill in the form opposite to watch Akintunde's presentation. 

Watch the presentation